Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janssen Gets US FDA Panel Nod For Additional COVID Vaccine Shot – But Is It A ‘Booster’?

Executive Summary

Advisory committee members say clinical data proves the second shot should be considered part of the primary series, while Janssen wants it called a single-shot vaccine with a booster.

You may also be interested in...



ACIP Prefers mRNA COVID-19 Vaccines, But Worries Message May Not Resonate

Advisory committee says that clinical guidelines and other communications must include strong belief mRNA vaccines should be given over Janssen’s adenovirus vaccine.

Woodcock Outlines Priorities For Next US FDA Commissioner

Along with the pandemic, user fees, IT upgrades and nutrition issues should be at the top of the list, the acting commissioner said.

Woodcock Outlines Priorities For Next US FDA Commissioner

Along with the pandemic, user fees, IT upgrades and nutrition issues should be at the top of the list, the acting commissioner said.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel